Japan’s IP office upholds CRISPR patent and allows third
01-06-2021
CRISPR specialist raises $80m in funding
28-09-2018
Mark_Kuiken / iStockphoto.com
Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Allergan, Editas, agreement, R&D, CRISPR, genome editing, ocular, eye disease, patent, licensing
